<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"><channel><title>Stroke survivors get FDA-approved daily pill shown to cut repeat risk by 26% — Live Feed</title><link>https://www.live-feeds.com/feed/stroke-survivors-get-fda-approved-daily-pill-shown-to-cut-repeat-risk-by-26</link><atom:link xmlns:atom="http://www.w3.org/2005/Atom" href="https://www.live-feeds.com/feed/stroke-survivors-get-fda-approved-daily-pill-shown-to-cut-repeat-risk-by-26/rss.xml" rel="self" type="application/rss+xml"/><description>Continuously updated, source-cited coverage.</description>
<item><title>FDA approves first factor XIa inhibitor for secondary stroke prevention</title><link>https://www.live-feeds.com/feed/stroke-survivors-get-fda-approved-daily-pill-shown-to-cut-repeat-risk-by-26</link><guid isPermaLink="false">https://www.live-feeds.com/feed/stroke-survivors-get-fda-approved-daily-pill-shown-to-cut-repeat-risk-by-26#u207587</guid><pubDate>Wed, 18 Nov 2026 21:06:00 +0000</pubDate><description>The U.S. Food and Drug Administration has approved Sunharbo (asundexian) 50 mg tablets, in combination with antiplatelet therapy, to reduce the risk of stroke in adults following a recent mild-to-moderate noncardioembolic ischemic stroke or high-risk transient ischemic attack. The daily pill represents the first factor XIa inhibitor cleared for this indication. Clinical data showed the treatment cuts repeat stroke risk by 26 percent. Bayer manufactures the drug, which introduces a new class of antithrombotic therapy for secondary stroke prevention.Why it mattersFactor XIa inhibitors target a d</description></item>
</channel></rss>